🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Here is a recent update on the VA's lung cancer screening activities. #lcsm Veterans Health VA Research

A new Dutch study demonstrates a clear advantage of SBRT over Surgery for early-stage NSCLC. 🇳🇱 #radonc sciencedirect.com/science/articl…

#Stereotactic #radiotherapy for neovascular age-related macular degeneration (STAR): a pivotal, randomised, double-masked, sham-controlled device trial, published in The Lancet. 👉 Read it before your patients: bit.ly/3NRZbrz

More work needs to be done in early stage NSCLC. AI can guide us choosing SABR regimens, IO options.

In Japan, lung SBRT is more cost-effective than surgery for patients with medically operable stage I NSCLC. 🇯🇵 #radonc redjournal.org/article/S0360-…

Urgent need for evidence on the role of PCI and MRI surveillance in all stages of Small Cell Lung Cancer in the era of immunotherapy 👉Please consider enrolling patients in the EORTC PRIMALUNG trial to contribute to advancing outcomes sciencedirect.com/science/articl…

We have published a simple-to-use dosimetry planning guide for high-quality Lung SBRT with worksheets and OAR checklists. It’s open access for all to view and download. #radonc

🇫🇷#SFRO2024 - Matthias Guckenberger gives an important update on E2Radiate registry and OligoCare cohort; run-rate 80 patients per month, currently n=>3000! 👏🏽👏🏽👏🏽Also describes a novel “living systematic review” platform - coming to you soon!!! #radonc

📊 An International EORTC Survey on Stage III NSCLC resectability: ✅ Resectable: Smaller tumors, w/ single-station N2 Larger tumours, w/ max N1 ❌ Unresectable: Bulky/invasive N2, N3 T4 tumours, w/ multi-station N2 Results shaped a consensual definition: lungcancerjournal.info/article/S0169-…

Nice contest for the Piedmont citizen of the year 2024! Please vote for my friend and brilliant colleague umberto ricardi, it takes just one click! quotidianopiemontese.it/2025/01/09/vot…

#ELCC25 in Paris has started with ESTRO being a partner of the meeting Such multidisciplinary meetings are THE place to learn from our neighboring disciplines & teach them about the value of Radiation Oncology Tomorrow: borderline resectable stage III NSCLC, hot topic

Great talk by Matthias Guckenberger on borderline resectable NSCLC at #ELCC25

Suresh Senan presenting exploratory analysis of #Adriatic study in #lungcancer at #ELCC25. Lowest risk of brainmets in #durva arm, esp when pci #radiotherapy is given as well.

Seguimos sin poner el foco en la causa: el desaforado consumo de carne roja y procesada en España, especialmente en algunas regiones. Yo me voy a la Fiesta de la Verdura de #Tudela.

📊 We need to incorporate PROs in our daily clinical practice, not just in clinical trials. 💫 #ESMOAmbassadors #ELCC25 #LCSM ESMO - Eur. Oncology

Induction chemo/IO followed by local TX is the trend for stage III NSCLC: 20-30% pCR, up to 50% MPR Surgery vs Radiotherapy? Non-invasive RT could achieve similar OS with better side effects: randomized study? First, Optimizing RT: 60 Gy in 15 FX vs chemo/RT 60 Gy in 30 FX

🫁 Selective SBRT can help patients with metastatic EGFR+ NSCLC get more MILEAGE out of every one of these drugs. Ask your radiation oncologist to learn more. Jill Feldman GO2 for Lung Cancer LUNGevity Foundation LungCancerAmerica ACS National Lung Cancer Roundtable

Matthias Guckenberger kicking of #ESTRO25

Huge thanks to Ben Slotman for organising the ESTRO Lung Focus Group mentor/mentee breakfast meeting this morning at #ESTRO25 Was lovely to meet everyone in person. Looking forward to stimulating discussions over the coming year

Just when you thought the horizon for locally advanced NSCLC couldn’t get brighter… along comes HORIZON-01: ChemoRadiotherapy followed by Alectinib, Entrectinib, or Pralsetinib. Thanks Millie Das MD for the heads up. #ATS2025 #RadOncMeetsTargetedTherapy